Search company, investor...

Molecular Biometrics

Founded Year



Dead | Dead

Total Raised


About Molecular Biometrics

Molecular Biometrics is applying metabolomic technologies to develop accurate, non-invasive methodologies for evaluating normal biologic function in health and disease, and for drug discovery and development. The company's technology is being applied in reproductive health, neurodegenerative disease (Alzheimer's disease and Parkinson's disease), maternal fetal medicine, pulmonary metabolism and edema, and lactate metabolism.

Headquarters Location

One Edgewater Drive Suite 110

Norwood, Massachusetts, 02062,

United States


Missing: Molecular Biometrics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Molecular Biometrics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Molecular Biometrics Frequently Asked Questions (FAQ)

  • When was Molecular Biometrics founded?

    Molecular Biometrics was founded in 2005.

  • Where is Molecular Biometrics's headquarters?

    Molecular Biometrics's headquarters is located at One Edgewater Drive, Norwood.

  • What is Molecular Biometrics's latest funding round?

    Molecular Biometrics's latest funding round is Dead.

  • How much did Molecular Biometrics raise?

    Molecular Biometrics raised a total of $24.5M.

  • Who are the investors of Molecular Biometrics?

    Investors of Molecular Biometrics include Oxford Bioscience Partners, Safeguard Scientifics and Atlas Venture.

  • Who are Molecular Biometrics's competitors?

    Competitors of Molecular Biometrics include DiscoveryBioMed, Echelon Biosciences, Phylogeny, Cellix, Proteostasis Therapeutics and 10 more.

Compare Molecular Biometrics to Competitors

Echelon Biosciences Logo
Echelon Biosciences

Echelon Biosciences is a company that received a SBIR Phase I grant for a project entitled: Near Infrared Substrates for Imaging Autotaxin Activity In Vivo. Their project aims to synthesize ATXRed, an in vivo imaging agent that is specifically activated by the enzymatic activity of autotaxin. Autotaxin is an extracellular enzyme that generates the phospholipid growth factor lysophophatidic acid (LPA). LPA is involved in a variety of biological functions, such as angiogenesis, wound healing, brain development, immunological competence and the regulation of blood pressure. Both LPA and autotaxin have also been implicated in numerous diseases, especially metastatic cancer. Autotaxin was identified as one of the 40 most induced genes in aggressive breast cancer. The broader impacts of this research are the discovery and commercialization of tools that easily highlight specific biological pathways in living organisms. ATXRed will be welcomed by basic researchers in many fields associated with autotaxin and LPA. However, the utility extends beyond the basic research sphere. ATXRed smart probes could also aid pharmaceutical researchers searching for pharmacological inhibitors of autotaxin and LPA receptor agonists and antagonists. ATXRed would be a powerful tool in many rodent models of human cancer. In vivo autotaxin imaging probes could also aid in the clinic by helping to identify and monitor disease progression and treatment. Ultimately, ATXRed could help guide surgical resection of tumorstumors previously identified by the smart probe to have elevated autotaxin activity. In total, ATXRed probes have the potential to impact basic research, drug discovery and the clinic as a prime example of molecular medicine applied from bench to bedside.

Transposagen Biopharmaceuticals

Transposagen Biopharmaceuticals produces genetically modified MutaRat Knockout Animal Models of human diseases for drug discovery and development. Per the company, the production of animal models is a $1.2 billion/year market and is expected to grow 12 percent annually through 2010.

Welichem Biotech

Welichem Biotech Inc. ("Welichem", TSX-V: WBI) is engaged in the discovery and development of small molecule therapeutics. Using its Symbiochem technology platform, the Company has developed a robust pipeline of patent-protected compounds that target autoimmune/inflammatory diseases and cancers. Welichem's lead drug candidate, WBI-1001, targets autoimmune/inflammatory skin disorders, such as psoriasis and eczema. A phase I clinical trial of WBI-1001, done in Montreal, in patients with psoriasis has shown a very good safety profile and promising efficacy. As well, the application of WBI-1001 cream against atopic dermatitis (a type of eczema) in a phase IIa clinical trial also has been completed in Canada, with the final report pending in the third quarter of 2008. Welichem plans to all the necessary Phase II Clinical Trials against psoriasis and eczema in the near future. In the company's pipeline, WBI-1001 related compounds are being evaluated also for their therapeutic potential against other autoimmune diseases such as, inflammatory bowel disease and rheumatoid arthritis. Welichem's other lead drug candidate, WBI-2100, selectively targets certain types of hard-to-treat cancerous tumours. This is achieved in part through inhibition of angiogenesis and metastasis. Animal tests have shown that WBI-2100 is effective as a monotherapy and also in increasing the effectiveness of several commonly used chemotherapeutic products. The uniqueness of this small molecule cancer chemotherapeutic is that in pre-clinical studies it increases the number of neutrophils in the peripheral blood. The boosting of neutrophils in animal studies in the presence of the cancer therapeutic, cyclophosphamide, supports its potential therapeutic application for chemotherapy induced neutropenia. With its proven Symbiochem; technology platform, Welichem will advance its pipeline of drug candidates at a rate and time commensurate with resources and target need, and is in a strong position to contribute effectively to productive drug discovery and development partnerships.


Kalypsys is a drug discovery company using a cellular ultra high-throughput system to carry out massive drug screening in cellular models of human disease and toxicology.

Carmot Therapeutics

Carmot Therapeutics is applying its technology, Chemotype Evolution, to address unmet chemical needs in drug discovery, focusing on high-profile targets for which drug leads have been difficult to identify. Carmot has built and optimized this platform to rapidly and efficiently unlock therapeutic target space not currently accessible to conventional small molecule technologies. Carmot is currently using Chemotype Evolution to discover novel drug candidates targeting validated pathways in metabolic disease, oncology, and inflammation. The company was founded in 2008 and is based in Berkeley, California.

Promentis Pharmaceuticals

Promentis Pharmaceuticals is a pharmaceutical company that develops compounds for the treatment of schizophrenia and other central nervous system disorders. Promentis' drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other diseases.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.